Drugs & Targets FDA approves nivolumab for adjuvant treatment of stage 2B/C melanoma October 20, 2023Vol.49 No.39
Drugs & Targets EC approves Keytruda as adjuvant treatment for NSCLC at high risk of recurrence October 20, 2023Vol.49 No.39
Drugs & Targets CHMP issues positive opinion for Keytruda + chemo as first-line treatment for HER2-negative, PD-L1-positive advanced gastric or GEJ cancer October 20, 2023Vol.49 No.39
Drugs & Targets EC approves Adcetris for adults with stage 3 Hodgkin lymphoma October 20, 2023Vol.49 No.39
Drugs & Targets CHMP issues positive opinion for Rubraca as a first-line maintenance treatment for advanced ovarian cancer October 20, 2023Vol.49 No.39
Drugs & Targets FDA approves encorafenib with binimetinib for metastatic NSCLC with a BRAF V600E mutation October 13, 2023Vol.49 No.38
Drugs & Targets Shasqi, Johnson & Johnson expand existing research collaboration October 13, 2023Vol.49 No.38
Drugs & Targets Delfi Diagnostics commercializes blood test for lung cancer screening October 13, 2023Vol.49 No.38
Drugs & Targets FDA grants first marketing authorization for DNA test to assess predisposition for dozens of cancer types October 06, 2023Vol.49 No.37
Drugs & Targets FDA grants priority review to odronextamab for R/R follicular lymphoma and R/R diffuse large B-cell lymphoma October 06, 2023Vol.49 No.37
